While targeting TAAs offers promising therapeutic potential, several challenges remain:
Heterogeneity: TAAs can vary significantly between individuals and even within different regions of a single tumor. Immune Tolerance: Since some TAAs are also expressed on normal cells, the immune system may not always recognize them as foreign. Tumor Escape Mechanisms: Cancer cells can alter the expression of TAAs to evade immune detection.
